Drug Profile


Alternative Names: Boronated porphyrin compound

Latest Information Update: 26 Mar 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procept
  • Class Antineoplastics; Oxidants
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Brain cancer; Glioma

Most Recent Events

  • 26 Mar 2003 No development reported - Phase-II for Brain cancer in Australia (unspecified route)
  • 26 Mar 2003 No development reported - Preclinical for Glioma in USA (unspecified route)
  • 21 Feb 2000 Procept has merged with Heaven's Door Corporation to form
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top